Robert Alan Fenstermaker

Title: The Innovative Contributions of Robert Alan Fenstermaker

Introduction

Robert Alan Fenstermaker is a notable inventor based in Amherst, NY, with a significant portfolio of seven patents. His work primarily focuses on advancements in cancer therapy, particularly through the development of specific antibodies and methods for evaluating tumor progression.

Latest Patents

Fenstermaker's latest patents include groundbreaking innovations such as anti-survivin antibodies for cancer therapy. This patent provides survivin-specific antibodies, nucleic acids encoding these antibodies, and methods for treating tumors that express survivin. The compositions have been shown to effectively inhibit tumor growth. Another significant patent involves circulating survivin-positive exosomes, which outlines a method for evaluating glioma progression by monitoring levels of circulating exosomes that are positive for survivin and a glial marker. An increase in these exosomes indicates a poor prognosis and can be used to assess the efficacy of glioma therapies.

Career Highlights

Throughout his career, Fenstermaker has worked with reputable organizations such as Health Research, Inc. and Kinex Pharmaceuticals, LLC. His contributions to the field of cancer research have been instrumental in developing new therapeutic strategies.

Collaborations

Fenstermaker has collaborated with notable colleagues, including Michael J. Ciesielski and David G. Hangauer, Jr. These partnerships have further enhanced his research and innovation in cancer therapies.

Conclusion

Robert Alan Fenstermaker's innovative work in cancer therapy through his patents and collaborations highlights his significant contributions to medical science. His advancements continue to pave the way for improved treatment options for patients.